Effect of spacing intravenous bisphosphonates in patients with multiple myeloma in plateau phase [16]

Leukemia

Volumn 21, Issue 7, 2007, Pages 1596-1599

  Park, Sophie ^a   Borderie, D ^a   Cormier, C ^a   Bouscary, D ^a   Roux, C ^a   Job Deslandre, C ^a   Merlat, A ^b   Cherreau, B ^a   Souberbielle, J C ^a   Dreyfus, F ^a  

^a APHP ^*  (France)

^b NOVARTIS PHARMA K K   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; DEXAMETHASONE; OSTEOCALCIN; PAMIDRONIC ACID; THALIDOMIDE; UNCLASSIFIED DRUG; UVEDOSE; ZOLEDRONIC ACID;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE DISEASE; BONE NECROSIS; BONE REMODELING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE EXACERBATION; DOSE TIME EFFECT RELATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; JAW DISEASE; KIDNEY FAILURE; LETTER; MALE; MULTIPLE MYELOMA; OPEN STUDY; OSSIFICATION; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; TREATMENT DURATION;

EID: 34250717360     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404715     Document Type: Letter

References (8)

1. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20: 3719-3736.
2. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91: 1191-1200.
3. Ali SM, Esteva FJ, Hortobagyi G, Harvey H, Seaman J, Knight R et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001; 19: 3434-3437.
4. Landesberg R, Wilson T, Grbic JT. Bisphosphonate-associated osteonecrosis of the jaw: Conclusions based on an analysis of case series. Dent Today 2006; 25: 52, 54-57.
5. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006; 81: 1047-1053.
6. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
7. Terpos E, Politou M, Szydlo R, Nadal E, Avery S, Olavarria E et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia 2004; 18: 1420-1426.
8. Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/ relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005; 19: 1969-1976.